Alcohol Septal Ablation

1. Maron BJ, McKenna WJ, Danielson GK, Kappenberger LJ, Kuhn HJ, Seidman CE, et al. American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol. 2003;42(9):1687-713.2).Search in Google Scholar

2. Maron BJ, Dearani JA, Ommen SR, Maron MS, Schaff HV, Gersh BJ, et al. The case for surgery in obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2004;44(10):2044-53.10.1016/j.jacc.2004.04.063Search in Google Scholar

3. Holmes DR Jr., Valeti US, Nishimura RA. Alcohol septal ablation for hypertrophic cardiomyopathy: indications and technique. Catheter Cardiovasc Interv. 2005;66(3):375-89.10.1002/ccd.20500Search in Google Scholar

4. Singh M, Edwards WD, Holmes DR Jr, Tajil AJ, Nishimura RA. Anatomy of the first septal perforating artery: a study with implications for ablation therapy for hypertrophic cardiomyopathy. Mayo Clin Proc. 2001;76(8):799-802.10.1016/S0025-6196(11)63224-2Search in Google Scholar

5. Faber L, Ziemssen P, Seggewiss H. Targeting percutaneous transluminal septal ablation for hypertrophic obstructive cardiomyopathy by intraprocedural echocardiographic monitoring. J Am Soc Echocardiogr. 2000;13(12):1074-9.10.1067/mje.2000.108250Search in Google Scholar

6. Monakier D, Woo A, Puri T, Schwartz L, Ross J, Jamorski M, et al. Usefulness of myocardial contrast echocardiographic quantification of risk area for predicting postprocedural complications in patients undergoing septal ethanol ablation for obstructive hypertrophic cardiomyopathy. Am J Cardiol. 2004;94(12):1515-22.10.1016/j.amjcard.2004.08.030Search in Google Scholar

7. Faber L, Seggewiss H, Welge D, Fassbender D, Schmidt HK, Gleichmann U, et al. Echo-guided percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy: 7 years of experience. Eur J Echocardiogr. 2004;5(5):347-55.10.1016/j.euje.2004.01.001Search in Google Scholar

8. Chang SM, Nagueh SF, Spencer WH 3rd, Lakkis NM. Complete heart block: determinants and clinical impact in patients with hypertrophic obstructive cardiomyopathy undergoing nonsurgical septal reduction therapy. J Am Coll Cardiol. 2003;42(2):296-300.10.1016/S0735-1097(03)00623-5Search in Google Scholar

9. Kuhn H, Lawrenz T, Lieder F, Leuner C, Strunk-Mueller C, Obergassel L, et al. Survival after transcoronary ablation of septal hypertrophy in hypertrophic obstructive cardiomyopathy (TASH): a 10 year experience. Clin Res Cardiol. 2008;97(4):234-43.10.1007/s00392-007-0616-718071624Search in Google Scholar

10. Bhagwandeen R, Woo A, Ross J, Wigle ED, Rakowski H, Kwinter J, et al. Septal ethanol ablation for hypertrophic obstructive cardiomyopathy: early and intermediate results of a Canadian referral centre. Can J Cardiol. 2003;19(8):912-7.Search in Google Scholar

11. Veselka J, Duchonová R, Procházková S, Homolová I, Pálenícková J, Zemánek D, et al. The biphasic course of changes of left ventricular outflow gradient after alcohol septal ablation for hypertrophic obstructive cardiomyopathy. Kardiol Pol. 2004;60(2):133-6.Search in Google Scholar

12. Sorajja P, Valeti U, Nishimura R, Ommen S, Rihal C, Gersh B. Outcome of Alkohol septal ablation of obstructive hypertrophic cardiomiopaty. Circulation. 2008;118:131-139.10.1161/CIRCULATIONAHA.107.73874018591440Search in Google Scholar

13. Angelini P. The “1st septal unit” in hypertrophic obstructive cardiomyopathy: a newly recognized anatomo-functional entity, identified during recent alcohol septal ablation experience. Tex Heart Inst J. 2007;34(3):336-46.Search in Google Scholar

14. Yoerger DM, Picard MH, Palacios IF, Vlahakes GJ, Lowry PA, Fifer MA. Time course of pressure gradient response after first alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Am J Cardiol. 2006;97(10):1511-4.10.1016/j.amjcard.2005.12.04016679095Search in Google Scholar

15. Henein MY, O'Sullivan CA, Ramzy IS, Sigwart U, Gibson DG. Electromechanical left ventricular behavior after nonsurgical septal reduction in patients with hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol. 1999;34(4):1117-22.10.1016/S0735-1097(99)00332-0Search in Google Scholar

16. van Dockum WG, Kuijer JP, Götte MJ, Ten Cate FJ, Ten Berg JM, Beek AM, et al. Septal ablation in hypertrophic obstructive cardiomyopathy improves systolic myocardial function in the lateral (free) wall: a follow-up study using CMR tissue tagging and 3D strain analysis. Eur Heart J. 2006;27(23):2833-9.10.1093/eurheartj/ehl35817098761Search in Google Scholar

17. van Dockum WG, Beek AM, ten Cate FJ, ten Berg JM, Bondarenko O, Götte MJ, et al. Early onset and progression of left ventricular remodeling after alcohol septal ablation in hypertrophic obstructive cardiomyopathy. Circulation. 2005;111(19): 2503-8.10.1161/01.CIR.0000165084.28065.0115867172Search in Google Scholar

18. Mazur W, Nagueh SF, Lakkis NM, Middleton KJ, Killip D, Roberts R, et al. Regression of left ventricular hypertrophy after nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. Circulation. 2001;103(11):1492-6.10.1161/01.CIR.103.11.149211257074Search in Google Scholar

19. Veselka J, Prochazkova S, Bolomova-Homolova I, Duchonova R, Tesar D. Effects of alcohol septal ablation for hypertrophic obstructive cardiomyopathy on Doppler Tei index: a midterm follow-up. Echocardiography. 2005;22(2):105-9.10.1111/j.0742-2822.2005.03148.x15693775Search in Google Scholar

20. Nagueh SF, Lakkis NM, Middleton KJ, Killip D, Zoghbi WA, Quiñones MA, et al. Changes in left ventricular diastolic function 6 months after nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. Circulation. 1999;99(3):344-7.10.1161/01.CIR.99.3.344Search in Google Scholar

21. El-Jack SS, Nasif M, Blake JW, Dixon SR, Grines CL, O'Neill WW. Predictors of complete heart block after alcohol septal ablation for hypertrophic cardiomyopathy and the timing of pacemaker implantation. J Interv Cardiol. 2007;20(1):73-6.10.1111/j.1540-8183.2007.00220.x17300408Search in Google Scholar

22. Faber L, Welge D, Fassbender D, Schmidt HK, Horstkotte D, Seggewiss H. Percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy: managing the risk of procedure related AV conduction disturbances. Int J Cardiol. 2007;119(2):163-7.10.1016/j.ijcard.2006.07.17917067708Search in Google Scholar

23. Faber L, Seggewiss H, Welge D, Fassbender D, Ziemssen P, Schmidt HK, et al. Predicting the risk of atrioventricular conduction lesions after percutaneous septal ablation for obstructive hypertrophic cardiomyopathy. Z Kardiol. 2003;92(1):39-47.10.1007/s00392-003-0878-712545300Search in Google Scholar

24. Knight CJ. Alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Heart. 2006;92(9):1339-44.10.1136/hrt.2005.063677186120416908721Search in Google Scholar

25. Gietzen FH, Leuner CJ, Raute-Kreinsen U, Dellmann A, Hegselmann J, Strunk-Mueller C, et al. Acute and longterm results after transcoronary ablation of septal hypertrophy TASH). Catheter interventional treatment for hypertrophic obstructive cardiomyopathy. Eur Heart J. 1999;20(18):1342-54.10.1053/euhj.1999.152010462469Search in Google Scholar

26. Kuhn H, Seggewiss H, Gietzen FH, Boekstegers P, Neuhaus L, Seipel L. Catheter-based therapy for hypertrophic obstructive cardiomyopathy. First in-hospital outcome analysis of the German TASH Registry. Z Kardiol. 2004;93(1):23-31.10.1007/s00392-004-1028-614740238Search in Google Scholar

27. Hori Y, Ueda M, Nakayama T, Saegusa N, Uehara M, Lee K, et al. Occurrence of de novo sustained monomorphic ventricular tachycardia induced after percutaneous transluminal alcohol septal myocardial ablation for hypertrophic obstructive cardiomyopathy. Int J Cardiol. 2007;119(3):403-7.10.1016/j.ijcard.2006.07.18217069908Search in Google Scholar

28. Simon RD, Crawford FA 3rd, Spencer WH 3rd, Gold MR. Sustained ventricular tachycardia following alcohol septal ablation for hypertrophic obstructive cardiomyopathy. Pacing Clin Electrophysiol. 2005;28(12):1354-6.10.1111/j.1540-8159.2005.00278.x16403169Search in Google Scholar

29. Boltwood CM Jr., Chien W, Ports T. Ventricular tachycardia complicating alcohol septal ablation. N Engl J Med. 2004;351(18):1914-5.10.1056/NEJM20041028351182415509832Search in Google Scholar

30. McGregor JB, Rahman A, Rosanio S, Ware D, Birnbaum Y, Saeed M. Monomorphic ventricular tachycardia: a late complication of percutaneous alcohol septal ablation for hypertrophic cardiomyopathy. Am J Med Sci. 2004;328(3):185-8.10.1097/00000441-200409000-0001115367880Search in Google Scholar

31. Alam M, Dokainish H, Lakkis N. Alcohol septal ablation for hypertrophic_obstructive cardiomyopathy: a systematic review of published studies. J Interv Cardiol. 2006;19(4):319-27.10.1111/j.1540-8183.2006.00153.x16881978Search in Google Scholar

32. van Dockum WG, ten Cate FJ, ten Berg JM, Beek AM, Twisk JW, Vos J, et al. Myocardial infarction after percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: evaluation by contrast-enhanced magnetic resonance imaging. J Am Coll Cardiol. 2004;43(1):27-34.10.1016/j.jacc.2003.08.03114715178Search in Google Scholar

33. Zeng Z, Wang F, Dou X, Zhang S, Pu J. Comparison of percutaneous transluminal septal myocardial ablation versus septal myectomy for the treatment of patients with hypertrophic obstructive cardiomyopathy--a meta analysis. Int J Cardiol. 2006;112(1):80- 4.10.1016/j.ijcard.2005.10.00916507323Search in Google Scholar

34. Fifer MA. Controversies in cardiovascular medicine. Most fully informed patients choose septal ablation over septal myectomy. Circulation. 2007;116(2):207-16.10.1161/CIRCULATIONAHA.107.68813517620520Search in Google Scholar

35. Nagueh SF, Buergler JM, Quinones MA, Spencer WH 3rd, Lawrie GM. Outcome of surgical myectomy after unsuccessful alcohol septal ablation for the treatment of patients with hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol. 2007;50(8):795-8.10.1016/j.jacc.2007.04.065Search in Google Scholar

36. Ralph-Edwards A, Woo A, McCrindle BW, Shapero JL, Schwartz L, Rakowski H, et al. Hypertrophic obstructive cardiomyopathy: comparison of outcomes after myectomy or alcohol ablation adjusted by propensity score. J Thorac Cardiovasc Surg. 2005;129(2):351-8.10.1016/j.jtcvs.2004.08.047Search in Google Scholar

37. Nagueh SF, Ommen SR, Lakkis NM, Killip D, Zoghbi WA, Schaff HV, et al. Comparison of ethanol septal reduction therapy with surgical myectomy for the treatment of hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol. 2001;38(6):1701-6.10.1016/S0735-1097(01)01614-XSearch in Google Scholar

38. Firoozi S, Elliott PM, Sharma S, Murday A, Brecker SJ, Hamid MS, et al. Septal myotomymyectomy and transcoronary septal alcohol ablation in hypertrophic obstructive cardiomyopathy. A comparison of clinical, haemodynamic and exercise outcomes. Eur Heart J. 2002;23(20):1617-24.10.1053/euhj.2002.328512323162Search in Google Scholar